Showing 11-20 of 67 results for "".
- Martin Azzam, BS/BAhttps://practicaldermatology.com/profiles/martin-azzam-bsba/Onx4lV/
- Martin Metz, MDhttps://practicaldermatology.com/profiles/martin-metz-md/L090k9/
- Martina J. Porter, MDhttps://practicaldermatology.com/profiles/martina-j-porter-md/jlMneG/
AK Treatment Pearls
https://practicaldermatology.com/topics/skin-cancer-photoprotection/ak-treatment-pearls/19731/Joel Cohen, MD and George Martin, MD go in depth to discuss nuances of treating actinic keratosis in a wide ranging conversation covering the concept of painless PDT and how pretreatment may enhance penetration, an update on ingenol mebutate, and a potential role for combination calcipotriene and 5-Scientifically Speaking: Optimized Approaches to AK Management
https://practicaldermatology.com/topics/skin-cancer-photoprotection/scientifically-speaking-optimized-approaches-to-ak-management/19912/What's new in AK therapy? From a new, first-in-class molecule to updated approaches with long-standing treatments, the management of actinic keratosis continues to evolve. Scientifically Speaking host Joel L. Cohen, MD speaks with Neal Bhatia, MD, Michael H. Gold, MD, and George Martin, MD about theCutaneous Oncology
https://practicaldermatology.com/topics/skin-cancer-photoprotection/cutaneous-oncology/18638/Maui Derm Course Director George Martin, MD, recaps the discussion from the Cutaneous Oncology session during Maui Derm 2016. He shares his protocol for short-contact PDT therapy with an abbreviated incubation for reducing pain during treatment. Dr. Martin also offers an important clinical pearl forActinic Keratosis: Therapy Overview
https://practicaldermatology.com/topics/skin-cancer-photoprotection/actinic-keratosis-therapy-overview/19732/Joel Cohen, MD interviews George Martin, MD about the latest developments in actinic keratosis. Dr. Martin said he is eagerly awaiting regulatory review of tirbanibulin, which showed promising results in clinical trials. The two also discuss practical tips and nuances of using 5FU in practice. *Be sAloha Maui Derm
https://practicaldermatology.com/topics/psoriasis/aloha-maui-derm/19715/What is the magic that makes Maui Derm so special? Joel Cohen, MD and meeting founder and director George Martin, MD, go behind the scenes of one of the most popular meetings in dermatology.AK Therapy: Real-life Approaches to Combinations on Scientifically Speaking
https://practicaldermatology.com/topics/skin-cancer-photoprotection/ak-therapy-real-life-approaches-to-combinations-on-scientifically-speaking/19913/From serial PDT to novel combinations, specialists describe how they treat AKs in real-world settings. Scientifically Speaking host Joel L. Cohen, MD reviews cases from Neal Bhatia, MD, Michael H. Gold, MD, and George Martin, MD.- Ruxolitinib Cream 1.5% Effective in Hidradenitis Suppurativa Hurley Stage 1 or 2 Patientshttps://practicaldermatology.com/news/ruxolitinib-cream-15-shows-efficacy-for-hidradenitis-suppurativa-hurley-stage-1-or-2-patients/2462427/Data from a new phase 2 trial indicate twice-daily ruxolitinib cream, 1.5% (OpzeluraTM, Incyte) in adult patients with Hurley stage 1 or 2 (mild-to-moderate) hidradenitis suppurativa (HS) was safe and effective. The primary endpoint of the study was achieved, with patients on treatment with ruxolit…